MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) announced today the introduction of the ACQUITY™ UPLC PLUS Series, three new ACQUITY UltraPerformance LC™ (UPLC™) Systems that build off ...

ACQUITY™ Premier UPLC™ System: The next evolution in separation science is here. Maximizing the sensitivity, repeatability, and robustness of your LC and LC-MS applications is critical. The ACQUITY ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

The approval of ACQUITY UPLC is important for Waters as well as China. Notably, this marks the second medical device approval for Waters, the first being a neonatal screening solution which included ...

The company’s next-generation ultraperformance liquid chromatography platform is designed to meet the evolving laboratory requirements for chromatographic performance. Waters’ Acquity ultraperformance ...

Waters Corporation celebrated the ten-year anniversary of the ACQUITY UltraPerformance LC (UPLC) System. Over the last ten years, ACQUITY UPLC has had a major effect on laboratories worldwide, both ...

Pre-recorded webinar available for immediate playback. Traditional method development, in which an LC method is developed principally by trial-and-error, is time consuming and may not result in a ...

“In 2004, we changed the game. High Performance Liquid Chromatography (HPLC) wasn't keeping pace with business demands to analyze more samples, faster and with better results. The introduction of ...

The ACQUITY UPLC I-Class PLUS System offers industry-leading separations performance, opening up new possibilities for maximizing the resolution and sensitivity of your methods, improving the ...

Waters Corporation announced that the Waters ACQUITY UPLC I-Class IVD/Xevo TQ-S micro IVD System is now manufactured as a U. FDA Class I medical device and is CE Marked to the European Directive 98/79 ...